Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.

Ajay K SinghKevin CarrollJohn Joseph Valentine McMurrayScott SolomonVivekananda JhaKirsten L JohansenRenato D LopesIain C MacdougallGregorio T ObradorSushrut S WaikarChristoph WannerDavid C WheelerAndrzej WięcekAllison BlackorbyBorut CizmanAlexander R CobitzRich DaviesTara L DiMinoLata KlerAmy M MeadowcroftLin TaftVlado Perkovicnull null

Published in: The New England journal of medicine (2021)

Among patients with CKD and anemia who were not undergoing dialysis, daprodustat was noninferior to darbepoetin alfa with respect to the change in the hemoglobin level from baseline and with respect to cardiovascular outcomes. (Funded by GlaxoSmithKline; ASCEND-ND ClinicalTrials.gov number, NCT02876835.).

Keyphrases

chronic kidney disease
end stage renal disease
peritoneal dialysis
ejection fraction
iron deficiency
patient reported outcomes
red blood cell
combination therapy